jetcityimage/iStock Editorial via Getty Images Eli Lilly’s ( NYSE: LLY ) treatment for early Alzheimer's disease has been approved for use in Japan. Kisunla (donanemab-azbt), which is given via infusion once a month, is indicated for treatment of adults with early symptomatic Alzheimer's disease. The application was based.
